

27 February 2020

ASX Code: MXC

Notice Under Section 708A(5)(e) of the Corporations Act

A
S
X

R
E
L
E
A
S
E

MGC Pharmaceuticals Limited (ACN 116 800 269) (ASX:MXC) (**Company**), confirms the Company completed the placement of 31,250,000 fully paid ordinary shares (**Shares**) at an issue price of A\$0.032 each to raise A\$1,000,000 as previously announced and included in the Appendix 2A released 25 February 2020.

The Company gives notice pursuant to section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) that:

1. the Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act; and
2. as at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (b) section 674 of the Corporations Act; and
3. as at the date of this notice, there is no information to be disclosed which is excluded information (as defined in section 708A(7) of the Corporations Act) that is reasonable for investors and their professional advisers to expect to find in a disclosure document.

--Ends--

Authorised for issue by the Company Secretary, Rachel Kerr, for further information, please contact:

UK IR/Media Advisors

Catherine Leftley/Megan Dennison

St Brides Partners Ltd

+44 (0) 207 236 1177

megan@stbridespartners.co.uk

catherine@stbridespartners.co.uk

MGC Pharmaceuticals Ltd

Brett Mitchell

Executive Chairman

+61 8 6382 3390

info@mgcpharma.com.au